Ocugen OCGN
NASDAQ OCGN
$1.36 +0.01 (+0.74%)
At close: Sep 4, 2026 · 4:00 PM EDT

Ocugen (OCGN) Amortization of Deferred Charges (2014 - 2026)

Ocugen's (OCGN) quarterly Amortization of Deferred Charges came in at $25000.0 in Q1 2026, down 91.67% YoY from $300000.0 in Q1 2025, and little changed on a QoQ basis from $25000.0 in Q4 2025.

Analysis

Ocugen (OCGN) Amortization of Deferred Charges (2014 - 2026) Analysis & Trends

Ocugen (OCGN) has 10 years of Amortization of Deferred Charges data on file, last reported at $25000.0 in Q1 2026.

  • Quarterly Amortization of Deferred Charges fell 91.67% year-over-year to $25000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$175000.0 (down 160.98% YoY) and the FY2025 annual result came in at $100000.0, up 525.0% from the prior year.
  • Amortization of Deferred Charges steadied at $25000.0 in Q1 2026, from $25000.0 in the prior quarter.
  • In the past five years, Amortization of Deferred Charges ranged from a high of $300000.0 in Q1 2025 to a low of -$250000.0 in Q2 2025.
  • A 5-year average of $20000.0 and a median of $25000.0 in 2022 frame the typical range for Amortization of Deferred Charges.
  • The widest YoY moves for Amortization of Deferred Charges: up 934.48% in 2025, down 992.86% in 2025.
  • Tracing OCGN's Amortization of Deferred Charges over 5 years: stood at $25000.0 in 2022, then gained by 16.0% to $29000.0 in 2023, then plunged by 344.83% to -$71000.0 in 2024, then jumped by 135.21% to $25000.0 in 2025, then changed by 0.0% to $25000.0 in 2026.
  • The last three Amortization of Deferred Charges figures came in at $25000.0 (Q1 2026), $25000.0 (Q4 2025), and $25000.0 (Q3 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn
10 Ocugen 458.91 Mn 358.81 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 300,000.00
Mar 31, 2026 400,000.00
Jun 30, 2025 300,000.00
Mar 31, 2025 314,000.00
Dec 31, 2014 77,000.00
Sep 30, 2014 79,000.00
Jun 30, 2014 -80,000.00
Mar 31, 2014 -38,000.00